Showing results (241-250 of 757) with videos related to

Sort By:
Pageof 76
The Lancet. Gastroenterology & Hepatology|September 26, 2024
Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling studyMathias Jachs, Aitor Odriozola, Fanny Turon, et al.
The Lancet. Gastroenterology & Hepatology|September 22, 2024
Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysisBeatriz Gros, Jonathan Blackwell, Jonathan Segal, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2025
Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysisAdelina Artenie, Adam Trickey, Katharine J Looker, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2025
Precision surgery for hepatocellular carcinomaChristian Tibor Josef Magyar, Luckshi Rajendran, Zhihao Li, et al.
The Lancet. Gastroenterology & Hepatology|February 21, 2025
Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysisAntonio Liguori, Mirko Zoncapè, Giovanni Casazza, et al.
The Lancet. Gastroenterology & Hepatology|February 23, 2025
[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre studyJean-Charles Nault, Marouane Boubaya, Myriam Wartski, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2024
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trialKlara Dorman, Stefan Boeck, Karel Caca, et al.
The Lancet. Gastroenterology & Hepatology|December 8, 2022
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort studyZhigang Liu, Kaixing Le, Xin Zhou, et al.
The Lancet. Gastroenterology & Hepatology|July 17, 2021
Sleep and liver disease: a bidirectional relationshipThomas Marjot, David W Ray, Felicity R Williams, et al.
The Lancet. Gastroenterology & Hepatology|July 30, 2021
The economic burden of colorectal cancer across Europe: a population-based cost-of-illness studyRaymond Hugo Henderson, Declan French, Timothy Maughan, et al.
Pageof 76